期刊文献+

米氮平口腔崩解片治疗抑郁症患者的临床研究概述

Clinical applications of mirtazapine orally disintegrating tablets in depression treatment
原文传递
导出
摘要 除了研发新药以外,现有药物新剂型的研发和应用也是治疗抑郁症的新思路。口崩剂型抗抑郁药米氮平口腔崩解片凭借其便于携带、口感良好及易于吞服等优点,作为能较好改善抑郁症患者依从性的一种剂型在临床广泛应用。本文从疾病本身的特点,结合抗抑郁药物的药理特征和不良反应,介绍米氮平口腔崩解片在抑郁症患者的临床研究情况。 Besides developing new agents, the development and application of new formulation of present available agents is a new concept to treat depression. With the advantages of portability, good taste and easy swallowing, mirtazapine orally disintegrating tablets (ODT) is one kind of formulations widely used in clinic to improve the patient compliance. From the points of disease characteristics combined with the pharmacological activity and adverse reactions of antidepressant drugs, the paper reviewed the clinical applications of mirtazapine ODT in the depression treatment.
作者 任虹燕 李涛
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2014年第9期646-648,共3页 Chinese Journal of New Drugs and Clinical Remedies
基金 默沙东(中国)投资有限公司
关键词 抑郁症 米氮平 口腔崩解片 病人依从 吞咽障碍 deglutition disordersdepressive disorder mirtazapine orally disintegrating tablets patient compliance
  • 相关文献

参考文献19

  • 1HAIl ALI AFZALI H, KARNON J, GRAY J. A critical review of model- based economic studies of depression: modelling techniques, model structure and data sources[J]. Pharmacoecono- mics, 2012, 30(6): 461-482.
  • 2SZEGEDI A, RUJESCU D, TADIC A, et al. The catechol-O- methyhransferase Val108/158Met polymorphism affects short- term treatment response to mirtazapine, but not to paroxetine in major depression[J]. Pharmacozenomics J, 2005. 5 ( 1 ): 49-53.
  • 3袁勇贵,张心保.新型抗抑郁药米氮平[J].中国新药与临床杂志,2001,20(3):219-221. 被引量:52
  • 4ENGEL D, ZOMKOWSKI AD, LIEBERKNECHT V, et al. Chronic administration of duloxetine and mirtazapine downregulates proapoptotic proteins and upregulates neurotrophin gene expression in the hippocampus and cerebral cortex of mice [J]. J Psychiatr Res, 2013, 47(6) : 802-808.
  • 5ABELA JR, FISHMAN MB, COHEN JR, et al. Personality predispositions to depression in children of affectively- ill parients: the buffering role of self-esteem[J]. J Clin Child Adolesc Psychol, 2012, 41(4): 391-401.
  • 6ANDERSON B. Collaborative care and motivational interviewing: improving depression outcomes through patient empowerment interventions[J]. Am J Manag Care, 2007, 13 (4 Suppl): S103-5106.
  • 7GONZALEZ - VACAREZZA N, ABAD - SANTOS F, CARCAS - SANSUAN A, et al. Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6[J]. Pharmacogenomics J, 2013, 13(5) : 452-455.
  • 8KANG KW, KIM YG. Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone- metabolizing enzyme AKR1C(aldo-keto reductase) family caused by estradiol[J]. J Clin Pharmacol 2008, 48(12): 1430-1437.
  • 9RAJPUROHIT N, ARYAL SR, KHAN MA, et al. Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction[J]. S D Med, 2014, 67(4) : 137-139.
  • 10DEN HEUVEL M, KLEIJN H, PEETERS P. Bioequivalence trial of orally disintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers [J]. Clin Drug Investig, 200l, 21(6): 437-442.

二级参考文献4

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部